tirzepatide weight loss clinical trial FDA Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes Semaglutide vs Tirzepatide: Which GLP-1
Description
Right now, Semaglutide is still on the FDA shortage list, allowing compounding pharmacies to create versions to meet the demand
2023 [cited 2025 Mar 6]
Tirzepatide has not yet completed a comparable cardiovascular outcomes trial, though studies are underway and early signals are promising
Many PlexusDx patients who achieve weight loss goals choose to stay on a lower tirzepatide maintenance dose rather than stopping completelythis middle ground offers ongoing metabolic support without requiring the higher doses needed for active weight loss
